Canntab Therapeutics Limited Stock Performance
| CTABF Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of -2.68, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Canntab Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Canntab Therapeutics is expected to outperform it. At this point, Canntab Therapeutics has a negative expected return of -1.51%. Please make sure to confirm Canntab Therapeutics' variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Canntab Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Canntab Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1.5 M | |
| Total Cashflows From Investing Activities | 151.3 K |
Canntab |
Canntab Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.20 in Canntab Therapeutics Limited on August 29, 2024 and sell it today you would lose (0.19) from holding Canntab Therapeutics Limited or give up 95.0% of portfolio value over 90 days. Canntab Therapeutics Limited is currently producing negative expected returns and takes up 11.9689% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Canntab, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Canntab Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Canntab Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Canntab Therapeutics Limited, and traders can use it to determine the average amount a Canntab Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTABF |
Estimated Market Risk
| 11.97 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.51 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Canntab Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Canntab Therapeutics by adding Canntab Therapeutics to a well-diversified portfolio.
Canntab Therapeutics Fundamentals Growth
Canntab Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Canntab Therapeutics, and Canntab Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Canntab Pink Sheet performance.
| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (26.95) % | |||
| Current Valuation | 1.73 M | |||
| Shares Outstanding | 38.91 M | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 1.83 X | |||
| Revenue | 293.36 K | |||
| EBITDA | (2.49 M) | |||
| Cash And Equivalents | 691.11 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 126.2 K | |||
| Debt To Equity | 2.43 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (2.85 M) | |||
| Earnings Per Share | (0.1) X | |||
| Total Asset | 2.85 M | |||
About Canntab Therapeutics Performance
By analyzing Canntab Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Canntab Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Canntab Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Canntab Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.Things to note about Canntab Therapeutics performance evaluation
Checking the ongoing alerts about Canntab Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Canntab Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has high historical volatility and very poor performance | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
- Analyzing Canntab Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Canntab Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Canntab Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Canntab Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Canntab Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Canntab Therapeutics' pink sheet. These opinions can provide insight into Canntab Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Canntab Pink Sheet analysis
When running Canntab Therapeutics' price analysis, check to measure Canntab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canntab Therapeutics is operating at the current time. Most of Canntab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Canntab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canntab Therapeutics' price. Additionally, you may evaluate how the addition of Canntab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |